©TheCanadian Journal ofUrology™: International Supplement, April 2014
References
1. ClinesGA,GuiseTA.Molecularmechanismsand treatment of
bonemetastasis.
ExpertRevMolMed
2008;10: e7.
2. Lamothe F, Kovi J, Heshmat MY, Green EJ. Dissemination
ofprostaticcarcinoma:anautopsystudy.
JNatlMedAssoc
1986;
78(11):1083-1086.
3. Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer
mortality at 11 years of follow-up.
NEngl JMed
2012;366(11):
981-990.
4. Sartor O, Eisenberger M, KattanMW, Tombal B, Lecouvet F.
Unmet needs in the prediction anddetection ofmetastases in
prostate cancer.
Oncologist
2013;18(5):549-557.
5. KattanMW,YuC,StephensonAJ,SartorO,TombalB.Clinicians
versus nomogram: predicting future technetium-99m bone
scanpositivity inpatientswith risingprostate-specificantigen
after radical prostatectomy for prostate cancer.
Urology
2013;
81(5):956-961.
6. AdministrationFaD.ClinicalTrialEndpoints for theApproval
of Cancer Drugs and Biologics. 2007.
.
gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/ucm071590.pdf (accessed 20/10/
2013.
7. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral
density in patients with prostatic cancer treated with
orchidectomy andwith estrogens.
Calcif Tissue Int
1995;57(2):
97-99.
8. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM,
TavernierC.Bonemineraldensity inmen treatedwithsynthetic
gonadotropin-releasing hormone agonists for prostatic
carcinoma.
JUrol
1999;161(4):1219-1222.
9. DaniellHW.Osteoporosisafterorchiectomy forprostatecancer.
JUrol
1997;157(2):439-444.
10.Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z,
StrattePT.Progressiveosteoporosisduringandrogendeprivation
therapy forprostate cancer.
JUrol
2000;163(1):181-186.
11.Diamond T, Campbell J, Bryant C, Lynch W. The effect of
combined androgen blockade on bone turnover and bone
mineral densities in men treated for prostate carcinoma:
longitudinal evaluation and response to intermittent cyclic
etidronate therapy.
Cancer
1998;83(8):1561-1566.
12.SmithMR, McGovern FJ, Zietman AL et al. Pamidronate to
prevent bone loss during androgen-deprivation therapy for
prostate cancer.
NEngl JMed
2001;345(13):948-955.
13.MittanD,LeeS,MillerE,PerezRC,Basler JW,Bruder JM.Bone
loss following hypogonadism in men with prostate cancer
treatedwithGnRHanalogs.
JClinEndocrinolMetab
2002;87(8):
3656-3661.
14.Alibhai SM, Duong-HuaM, CheungAM et al. Fracture types
and risk factors in men with prostate cancer on androgen
deprivation therapy: a matched cohort study of 19,079 men.
JUrol
2010;184(3):918-923.
15.ShahinianVB,KuoYF,Freeman JL,Goodwin JS.Riskof fracture
after androgen deprivation for prostate cancer.
N Engl J Med
2005;352(2):154-164.
16.SmithMR,LeeWC,Brandman J,WangQ,BottemanM,Pashos
CL.Gonadotropin-releasinghormoneagonistsandfracturerisk:
aclaims-basedcohortstudyofmenwithnonmetastaticprostate
cancer.
JClinOncol
2005;23(31):7897-7903.
17.EbelingPR.Clinicalpractice.Osteoporosis inmen.
NEngl JMed
2008;358(14):1474-1482.
18.Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial
bonemineral densitymeasurements in patientmanagement?
J ClinDensitom
2002;5Suppl:S29-S38.
19.HeidenreichA,BastianP,BellmuntJetal.GuidelinesonProstate
Cancer. 2013.
_
Cancer_LR.pdf.AccessedOctober 1 2013.
20.Holzbeierlein JM. Managing complications of androgen
deprivation therapy for prostate cancer.
Urol Clin North Am
2006;33(2):181-190.
21.NetworkNCC. ProstateCancer. 2013.
professionals/physician_gls/pdf/prostate.pdf . Accessed
October 1 2013.
22.Lewiecki EM. RANK ligand inhibition with denosumab
for the management of osteoporosis.
Expert Opin Biol Ther
2006;6(10):1041-1050.
23.SmithMR, Egerdie B, Hernandez Toriz N et al. Denosumab
in men receiving androgen-deprivation therapy for prostate
cancer.
NEngl JMed
2009;361(8):745-755.
24.SmithMR,Eastham J,GleasonDM,ShashaD,TchekmedyianS,
Zinner N. Randomized controlled trial of zoledronic acid to
preventbonelossinmenreceivingandrogendeprivationtherapy
fornonmetastaticprostatecancer.
JUrol
2003;169(6):2008-2012.
25.Michaelson MD, Kaufman DS, Lee H et al. Randomized
controlled trial of annual zoledronic acid to prevent
gonadotropin-releasing hormone agonist-induced bone loss
inmenwithprostate cancer.
JClinOncol
2007;25(9):1038-1042.
26.Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of
once-weekly oral alendronate on bone loss inmen receiving
androgendeprivationtherapyforprostatecancer:arandomized
trial.
Ann InternMed
2007;146(6):416-424.
27.TombalB.Non-metastaticCRPCandasymptomaticmetastatic
CRPC: which treatment forwhichpatient?
AnnOncol
2012;23
Suppl 10:x251-258.
28.LogothetisCJ,LinSH.Osteoblasts inprostatecancermetastasis
tobone.
NatRevCancer
2005;5(1):21-28.
29.WeinfurtKP, LiY,Castel LD, et al. The significanceof skeletal-
related events for the health-related quality of life of patients
withmetastaticprostate cancer.
AnnOncol
2005;16(4):579-584.
30.OsterG,LameratoL,GlassAGetal.Naturalhistoryofskeletal-
related events inpatientswithbreast, lung, or prostate cancer
andmetastases tobone: a15-year study in two largeUShealth
systems.
SupportCareCancer
2013;21(12):3279-3286.
31.Fizazi K, Carducci M, Smith M et al. Denosumab versus
zoledronic acid for treatment of bonemetastases inmenwith
castration-resistantprostatecancer:arandomised,double-blind
study.
Lancet
2011;377(9768):813-822.
32.Saad F, Gleason DM, Murray R et al. Long-term efficacy of
zoledronic acid for thepreventionof skeletal complications in
patientswithmetastatic hormone-refractoryprostate cancer.
J
Natl Cancer Inst
2004;96(11):879-882.
33.DePuyV,AnstromKJ, Castel LD, SchulmanKA,WeinfurtKP,
SaadF. Effects of skeletalmorbidities on longitudinal patient-
reported outcomes and survival in patients with metastatic
prostate cancer.
SupportCareCancer
2007;15(7):869-876.
34.Hagiwara M, Delea TE, Saville MW, Chung K. Healthcare
utilization and costs associatedwith skeletal-related events in
prostate cancer patientswith bonemetastases.
Prostate Cancer
ProstaticDis
2013;16(1):23-27.
35.Ernst DS, Tannock IF, Winquist EW et al. Randomized,
double-blind, controlled trial of mitoxantrone/prednisone
and clodronate versusmitoxantrone/prednisone andplacebo
inpatientswithhormone-refractoryprostate cancer andpain.
JClinOncol
2003;21(17):3335-3342.
36.Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO.
Combined analysis of twomulticenter, randomized, placebo-
controlled studies of pamidronate disodium for the palliation
ofbonepain inmenwithmetastaticprostatecancer.
JClinOncol
2003;21(23):4277-4284.
37.Saad F, GleasonDM,MurrayR et al.A randomized, placebo-
controlled trial of zoledronic acid in patients with hormone-
refractory metastatic prostate carcinoma.
J Natl Cancer Inst
2002;94(19):1458-1468.
38.SaadF.Newresearchfindingsonzoledronicacid:survival,pain,
and anti-tumour effects.
CancerTreatRev
2008;34(2):183-192.
91
ButoescuANDTombal
